These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28328527)

  • 1. On the Conditional Power in Survival Time Analysis Considering Cure Fractions.
    Kuehnapfel A; Schwarzenberger F; Scholz M
    Int J Biostat; 2017 Mar; 13(1):. PubMed ID: 28328527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. geecure: An R-package for marginal proportional hazards mixture cure models.
    Niu Y; Wang X; Peng Y
    Comput Methods Programs Biomed; 2018 Jul; 161():115-124. PubMed ID: 29852954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NPHMC: an R-package for estimating sample size of proportional hazards mixture cure model.
    Cai C; Wang S; Lu W; Zhang J
    Comput Methods Programs Biomed; 2014; 113(1):290-300. PubMed ID: 24199658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A flexible futility monitoring method with time-varying conditional power boundary.
    Ying Zhang ; Clarke WR
    Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Mixture Cure Model Estimation in Bladder Cancer Patients: A Novel Approach with Exponentiated Weibull Exponential Distribution.
    Omer ME; Mustafa M; Ali N; Abd Rahman NH
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4167-4177. PubMed ID: 38156852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative views on setting clinical trial futility criteria.
    Gallo P; Mao L; Shih VH
    J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The exponentiated exponential mixture and non-mixture cure rate model in the presence of covariates.
    Mazucheli J; Coelho-Barros EA; Achcar JA
    Comput Methods Programs Biomed; 2013 Oct; 112(1):114-24. PubMed ID: 23932336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CureAuxSP: An R package for estimating mixture cure models with auxiliary survival probabilities.
    Ding J; Li J; Zhang M; Wang X
    Comput Methods Programs Biomed; 2024 Jun; 251():108212. PubMed ID: 38754327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semiparametric accelerated failure time cure rate mixture models with competing risks.
    Choi S; Zhu L; Huang X
    Stat Med; 2018 Jan; 37(1):48-59. PubMed ID: 28983935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
    Grant TS; Burns D; Kiff C; Lee D
    Pharmacoeconomics; 2020 Apr; 38(4):385-395. PubMed ID: 31848900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of a Mixture Cure Rate Model based on the Generalized Modified Weibull Distribution for the Analysis of Leukemia Patients.
    Omer ME; Abu Bakar M; Adam M; Mustafa M
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1045-1053. PubMed ID: 33906295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cure fraction estimation from the mixture cure models for grouped survival data.
    Yu B; Tiwari RC; Cronin KA; Feuer EJ
    Stat Med; 2004 Jun; 23(11):1733-47. PubMed ID: 15160405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power and sample size for survival analysis under the Weibull distribution when the whole lifespan is of interest.
    Heo M; Faith MS; Allison DB
    Mech Ageing Dev; 1998 May; 102(1):45-53. PubMed ID: 9663791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring a mixture of distributions using Minitab.
    Osman MI
    Comput Biol Med; 1997 May; 27(3):223-32. PubMed ID: 9215484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach.
    Wang X; George SL
    Clin Trials; 2023 Dec; 20(6):603-612. PubMed ID: 37366172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.